Multiple sclerosis is quietly shifting how drugmakers define success. Instead of judging a therapy mainly by whether it reduces relapses, developers are chasing the slower, harder-to-treat processes that drive long-term disability, and Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) is one of the companies building a therapy around that shift, through its myelin-focused candidate Lucid-MS.
For decades, MS treatment success was measured largely by relapse rates. Fewer flare-ups meant a drug was working. But researchers now recognize that a substantial proportion of long-term disability accumulates independent of relapses altogether, a phenomenon researchers call progression independent of relapse activity (PIRA). This realization has forced a re-evaluation of clinical trial endpoints and therapeutic goals, as reducing relapses alone may not be sufficient to preserve neurological function over time.
That shift has forced researchers to look at what is actually driving PIRA. A major suspect is chronic active lesions, sometimes called smoldering or mixed active-inactive lesions. These lesions, which are visible on MRI scans, are characterized by a rim of activated microglia and macrophages that slowly expand over time, leading to progressive tissue damage. Unlike acute inflammatory lesions that cause relapses, chronic active lesions are thought to contribute to the relentless accumulation of disability that occurs independently of clinical attacks. As a result, therapies that target these lesions could have a significant impact on long-term outcomes for people living with MS.
Rather than broadly suppressing the immune system, Quantum BioPharma’s Lucid-MS is designed to inhibit myelin degradation, preserve myelin and support functional recovery. By focusing on the underlying mechanisms of myelin damage, Lucid-MS aims to address the disease process that leads to disability accumulation, regardless of relapse activity. This approach represents a departure from traditional immunomodulatory therapies, which primarily target the inflammatory component of MS. The company believes that by preserving myelin, the protective sheath around nerve fibers, Lucid-MS may help slow or even prevent the progressive disability that is the greatest concern for patients.
The importance of this approach is underscored by recent research highlighting the role of PIRA in MS progression. Studies have shown that a large share of long-term disability accumulates independent of relapses, meaning that even patients with minimal relapse activity can experience significant worsening of their condition. This has led to a growing consensus that therapies must address not only acute inflammation but also the chronic, degenerative processes that drive disability. Quantum BioPharma’s focus on myelin preservation and functional recovery positions it at the forefront of this paradigm shift, potentially offering a new option for patients who continue to progress despite existing treatments.
As the MS treatment landscape evolves, the ability to address PIRA and chronic active lesions will become increasingly important for drug developers. Quantum BioPharma’s Lucid-MS, with its unique mechanism of action, represents a promising avenue for tackling these challenges. The company’s commitment to understanding the underlying drivers of disability, rather than just relapse rates, reflects a broader trend in neurology toward more targeted and disease-modifying therapies. While Lucid-MS is still in development, its potential to impact the lives of people with MS is significant, and the scientific community will be watching closely as clinical trials progress.
